SAN FRANCISCO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, was featured on an NBC Bay Area news segment, Tech Now!, with business and tech reporter Scott Budman. News cameras visited CollabRx headquarters with NBC reporters highlighting that "the battle against cancer just got a new high tech weapon, big data," and that "the fight against cancer has a new ally, and it doesn't come from a lab, it comes from a piece of powerful software."
CollabRx Chief Scientist, Smruti Vidwans, PhD, was interviewed for the segment and commented, "In the new information big data age, what you really need is a way to pull all of this information together. This is really where I think treatment for cancer is headed and I think drug development companies, diagnostic companies, all of these players are really important and the piece that we're providing is pulling it all together and bringing the right drug to the right people at the right time."
CollabRx Chairman and Chief Executive Officer Thomas Mika was also interviewed, mentioning "We have a declining cost of sequencing, meeting a lot of research that is finally identifying biomarkers and creating a lot of data that we turn into usable information."
"Information," Scott Budman points out, "that can be used as a weapon to battle cancer."
To view the video interview in its entirety please visit the following link:
http://www.nbcbayarea.com/news/local/Can-We-Kickstart-The-Fight-Against-Cancer-218388941.html?_osource=SocialFlowTwt_BAYBrand
About CollabRx
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.